Back to News & Events

Envisagenics Awarded $2M+ Direct to Phase II NCI SBIR Grant

Envisagenics announced that it has been awarded a Direct to Phase II SBIR grant from the National Cancer Institute (NCI). The award will provide more than $2 million over two years to support further development and commercialization of SpliceCore®, including SpliceDisco™, a new machine learning algorithm designed to connect cancer-specific therapeutic targets with the splicing mechanisms that drive disease. With this capability, Envisagenics can prioritize targets with strong biological rationale and therapeutic potential.

The project funded with this grant will support the development of SpliceDisco. By combining AI-driven prioritization with experimental validation, the project is designed to generate cancer-specific, partner-ready therapeutic target opportunities with defined disease relevance, patient prevalence, and modality fit across Envisagenics’ internal oncology pipeline and external collaboration programs.

Read more about the award, and Evisagenic’s SpliceCore® technology here.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => all
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 5065
                    [post_author] => 4
                    [post_date] => 2026-09-01 14:03:32
                    [post_date_gmt] => 2026-09-01 18:03:32
                    [post_content] => 

Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.

BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.

Application deadline: October 29, 2026, 5:00pm ET

For info sessions, eligibility and deadlines visit our REACH Website and FAQ.

The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.

Questions? Reach out to our program contacts or sign up for office hours:

Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here

Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here

[post_title] => BioREACH: Translational Research Funding Opportunity [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bioreach-translational-research-funding-opportunity [to_ping] => [pinged] => [post_modified] => 2026-09-04 11:55:36 [post_modified_gmt] => 2026-09-04 15:55:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5065 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 3225 [post_author] => 3 [post_date] => 2019-04-05 19:35:45 [post_date_gmt] => 2019-04-05 19:35:45 [post_content] => Join the Center for Biotechnology for Roche Oncology Strategic Interests Presentation on Monday April 15, 2019. Fiona Mack, PhD, Director External Innovation, Pharmaceutical Research and Early Development for the Roche Innovation Center New York will be at Stony Brook University Medical Center to present Roche’s strategic interests in Oncology, the process for asset evaluation and the various partnership models available to support discovery and early development programs. Fiona will also discuss Roche’s approach to investing in emerging novel therapeutics utilizing case studies as examples. April 15, 2019 10am-11am Radiation Oncology Conference Room (HOS L2-664) Stony Brook University Medical Center Level 2 Seating is limited. If you are interested in attending please contact Emily Kao at emily.kao@stonybrook.edu How to get to Stony Brook University Hospital Radiation Oncology Conference Room To access the Radiation Oncology Conference Room, please utilize the hospital main elevators and take down to Level 2. When you arrive on Level two proceed forward, following the signs to the "green elevators". You will find the Radiation Oncology conference room on your right hand side, room HOS L2-664 [post_title] => Roche Oncology: Strategic Interests Presentation [post_excerpt] => Join the Center for Biotechnology for a presentation on Roche’s strategic interests in Oncology, the process for asset evaluation and the various partnership models available to support discovery and early development programs. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => roche-oncology-strategic-interests-presentation [to_ping] => [pinged] => [post_modified] => 2019-04-05 19:57:03 [post_modified_gmt] => 2019-04-05 19:57:03 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3225 [menu_order] => 98 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 1417 [post_author] => 3 [post_date] => 2015-02-19 19:17:30 [post_date_gmt] => 2015-02-19 19:17:30 [post_content] => Presented by Clean Energy Business Incubator Program Wednesday, March 11, 2015 Long Island High Tech Incubator 3:30 PM - 5:00 PM: Seminar 5:00 PM - 7:00 PM: Mixer In most cases for a startup, having patent, trade secret, trademark, and/or copyright protection is the key leverage needed to attract the life-blood investment necessary to sustain and grow the startup to exit. This discussion will address from a startup's perspective how to maintain the maximum potential value of Intellectual Property you may have AND future Intellectual Property that you don't even know about yet! You will learn about:
  • Patent, Trademark, Copyright and Trade Secret Basics
  • Common misconceptions about IP, e.g., Patentability and enforcement vs. Freedom-to-Operate
  • Preparing for your pitch and the resultant Due Diligence
  • What steps to take (or not to take) in order to avoid losing your precious IP leverage: Unintentionally forfeiting IP rights,Controlling ownership,And other IP portfolio building strategies
Speakers: Ray Farrell, founding partner of Carter, DeLuca, Farrell & Schmidt, LLP; Pina Campagna, Patent & Trademark Attorney at Carter, DeLuca, Farrell & Schmidt, LLP. RSVP to David C Hamilton Director, Business Development, Clean Energy Business Incubator Program (CEBIP): david.hamilton@stonybrook.edu [post_title] => Startup Mission Critical: How to build an IP portfolio investors will want to invest in early and often [post_excerpt] => In most cases for a startup, having patent, trade secret, trademark, and/or copyright protection is the key leverage needed to attract the life-blood investment necessary to sustain and grow the startup to exit. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => startup-mission-critical-how-to-build-an-ip-portfolio-investors-will-want-to-invest-in-early-and-often [to_ping] => [pinged] => [post_modified] => 2016-03-02 18:02:01 [post_modified_gmt] => 2016-03-02 18:02:01 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/new/?p=1417 [menu_order] => 214 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3464 [post_author] => 3 [post_date] => 2020-03-24 14:02:59 [post_date_gmt] => 2020-03-24 14:02:59 [post_content] => The Center for Biotechnology team is working remotely in order to continue our efforts to support our community. We are available to help clients with their technology and/or business development concerns, and are exploring ways in which we can provide services, programs, and events in a productive, socially responsible way. We encourage you to stay in touch, and we provide updates to the community as things develop. Stay well, The Center for Biotechnology Team [post_title] => Moving Forward [post_excerpt] => During the time of the COVID-19 pandemic, the Center for Biotechnology team is working to support our community. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => moving-forward [to_ping] => [pinged] => [post_modified] => 2020-03-24 15:50:04 [post_modified_gmt] => 2020-03-24 15:50:04 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3464 [menu_order] => 72 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 5065 [post_author] => 4 [post_date] => 2026-09-01 14:03:32 [post_date_gmt] => 2026-09-01 18:03:32 [post_content] =>

Applications are now open for the 12th BioREACH Award Program from the Center for Biotechnology, which provides $50,000 in translational research funding for Stony Brook faculty and postdoctoral researchers to generate the evidence needed to advance promising innovations to the next stage of development.

BioREACH funds milestone-driven studies and welcomes biomedical innovations as well as platforms, tools, computational technologies, and other enabling technologies with the potential to contribute to solutions addressing unmet needs in health.

Application deadline: October 29, 2026, 5:00pm ET

For info sessions, eligibility and deadlines visit our REACH Website and FAQ.

The Center for Biotechnology (CfB) has helped advance some of Stony Brook University’s most impactful biomedical innovations, among them the yeast two-hybrid system, Xiaflex®, ReoPro®, Oracea®, and 3D virtual colonoscopy. The CfB has supported more than 475 faculty-led translational research projects and contributed to 306 license agreements generating $51 million in royalty returns to the University.

Questions? Reach out to our program contacts or sign up for office hours:

Dee Dao, PhD, Associate Director, dee.dao@stonybrook.edu
Office Hours: Monday–Friday, 2–3:30 PM | Sign up Here

Zelda Mendelowitz, PhD, Venture Associate, zelda.mendelowitz@stonybrook.edu
Office Hours: Tuesday, Wednesday, Friday, 8–11 AM | Sign up Here

[post_title] => BioREACH: Translational Research Funding Opportunity [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => bioreach-translational-research-funding-opportunity [to_ping] => [pinged] => [post_modified] => 2026-09-04 11:55:36 [post_modified_gmt] => 2026-09-04 15:55:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=5065 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 288 [max_num_pages] => 96 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) [query_cache_key:WP_Query:private] => )

BioREACH: Translational Research Funding Opportunity

More Information

Roche Oncology: Strategic Interests Presentation

More Information

Startup Mission Critical: How to build an IP portfolio investors will want to invest in early and often

More Information

Moving Forward

More Information